Arcutis (ARQT) CEO Todd Watanabe Sells 4,375 Shares

What Happened
Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics (ARQT), sold 4,375 shares in an open-market transaction on August 3, 2026. The weighted-average sale price was $26.12, for total proceeds of approximately $114,261. The filing states the sale was to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), a common, routine event when awards vest.

Key Details

• Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (appears timely within the SEC’s two-business-day window).
• Transaction type: Sale (S) — open market/private sale to satisfy tax withholding (footnote F1).
• Shares sold: 4,375; weighted-average price: $26.12; reported price range: $25.72–$26.69 across multiple trades (footnote F2). Reporting person offered to provide exact per-trade prices on request.
• Proceeds: ≈ $114,261.
• Shares owned after the transaction: Not specified in the provided filing.
• Notable footnotes: sale to cover RSU tax withholding (F1); price is weighted average with a range provided (F2); the filing notes various shares are held of record by trusts and entities (F3–F7) with disclaimers of beneficial ownership for some accounts.

Context
This was a sale tied to tax withholding on vested RSUs, which is generally considered a routine administrative disposition rather than a directional investment signal. The filing clarifies the sale covered tax obligations and provides a price range for multiple trades; the reporter is the company’s CEO and is associated with several trusts/accounts that hold additional shares (disclaimed in the filing).